YA CHEN SHIH

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis
    Ya Chen Tina Shih
    MEDTAP International, Inc, Bethesda, Maryland 20814, USA
    Clin Ther 24:701-16. 2002
  2. ncbi Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients
    Ya Chen Tina Shih
    Department of Biostatistics, Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Pharmacoeconomics 25:843-62. 2007
  3. ncbi Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?
    Ya Chen Tina Shih
    Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 58:231-44. 2008
  4. ncbi Brachytherapy for accelerated partial-breast irradiation: a rapidly emerging technology in breast cancer care
    Grace L Smith
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:157-65. 2011
  5. ncbi The association between symptom burdens and utility in Chinese cancer patients
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Qual Life Res 15:1427-38. 2006
  6. ncbi Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, Division of Quantitative Sciences, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 110:678-85. 2007
  7. ncbi Factors associated with immunotherapy use among newly diagnosed cancer patients
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, Division of Quantitative Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
    Med Care 47:948-58. 2009
  8. ncbi Does Medicare coverage of colonoscopy reduce racial/ethnic disparities in cancer screening among the elderly?
    Ya Chen Tina Shih
    Section ofHealth Services Research, Department of Biostatistics and Applied Mathematics, M D Anderson Cancer Center, University of Texas, Houston, USA
    Health Aff (Millwood) 25:1153-62. 2006
  9. ncbi Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients
    Ya Chen Tina Shih
    Departement of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Kidney Int 68:319-29. 2005
  10. ncbi Impact of generic drug entry on cost-effectiveness analysis
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Med Decis Making 25:71-80. 2005

Research Grants

  1. Economic Evaluations of Emerging Genomic Tests for Early Stage Breast Cancer
    YA CHEN SHIH; Fiscal Year: 2007
  2. Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?
    YA CHEN SHIH; Fiscal Year: 2009
  3. Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?
    Ya Chen Tina Shih; Fiscal Year: 2010

Detail Information

Publications26

  1. ncbi The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis
    Ya Chen Tina Shih
    MEDTAP International, Inc, Bethesda, Maryland 20814, USA
    Clin Ther 24:701-16. 2002
    ..The US Food and Drug Administration (FDA) recently held a meeting to determine whether the status of second-generation antihistamines (SGAs) should be switched from prescription (Rx) to over-the-counter (OTC) status...
  2. ncbi Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients
    Ya Chen Tina Shih
    Department of Biostatistics, Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Pharmacoeconomics 25:843-62. 2007
    ..We explored the impact of generic drug entry on the cost effectiveness of SSRIs...
  3. ncbi Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?
    Ya Chen Tina Shih
    Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 58:231-44. 2008
    ..We also highlight limitations of these economic evaluations and discuss why members of the cancer community should care about economic analyses...
  4. ncbi Brachytherapy for accelerated partial-breast irradiation: a rapidly emerging technology in breast cancer care
    Grace L Smith
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:157-65. 2011
    ..It is currently used in the community setting, although its efficacy has yet to be validated in prospective comparative trials. Frequency and factors influencing use have not been previously identified...
  5. ncbi The association between symptom burdens and utility in Chinese cancer patients
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Qual Life Res 15:1427-38. 2006
    ..This study explored the relationship between the M. D. Anderson Symptom Inventory (MDASI), an instrument measuring the severity of symptoms common to patients with cancer, and utility derived from the SF-36...
  6. ncbi Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, Division of Quantitative Sciences, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 110:678-85. 2007
    ..The objective of the project was to estimate the societal costs of uncontrolled CINV among working-age cancer patients...
  7. ncbi Factors associated with immunotherapy use among newly diagnosed cancer patients
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, Division of Quantitative Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
    Med Care 47:948-58. 2009
    ..Immunotherapy represents a newer modality for cancer treatment with substantial health benefits. However, the high costs of immunotherapy may create access barriers...
  8. ncbi Does Medicare coverage of colonoscopy reduce racial/ethnic disparities in cancer screening among the elderly?
    Ya Chen Tina Shih
    Section ofHealth Services Research, Department of Biostatistics and Applied Mathematics, M D Anderson Cancer Center, University of Texas, Houston, USA
    Health Aff (Millwood) 25:1153-62. 2006
    ..Overall, fewer than half of the elderly are screened, even though Medicare now covers colonoscopy...
  9. ncbi Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients
    Ya Chen Tina Shih
    Departement of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Kidney Int 68:319-29. 2005
    ..The number of end-stage renal disease (ESRD) enrollees and Medicare expenditures have increased dramatically. Pathways and associated Medicare expenditures in ESRD treatment need to be examined to potentially improve the efficiency of care...
  10. ncbi Impact of generic drug entry on cost-effectiveness analysis
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics and Applied Mathematics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Med Decis Making 25:71-80. 2005
    ..They conclude that incorporating generic drug entry into pharmacoeconomic models will yield more accurate projections of the ICER and lead to better decision making...
  11. ncbi Health care provider knowledge of drug formulary status in ambulatory care settings
    Ya Chen Tina Shih
    Department of Biostatistics and Applied Mathematics, Section of Health Services Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Health Syst Pharm 61:2657-63. 2004
    ..Health care providers' knowledge of whether the medications they prescribed were on the formulary of their patients' insurance plan and factors associated with this knowledge were examined...
  12. ncbi Disparities in colorectal screening between US-born and foreign-born populations: evidence from the 2000 National Health Interview Survey
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Cancer Educ 23:18-25. 2008
    ..This study examines the disparities in colorectal cancer (CRC) screening between US- and foreign-born groups and explores factors associated with such disparities...
  13. ncbi Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Pharmacoeconomics 27:947-61. 2009
    ..e. 3 years) of CEF compared with CMF. It is possible that a future analysis will reach a different conclusion when more years of follow-up data become available...
  14. ncbi Immunotherapy in the initial treatment of newly diagnosed cancer patients: utilization trend and cost projections for non-Hodgkin's lymphoma, metastatic breast cancer, and metastatic colorectal cancer
    Ya Chen Tina Shih
    Health Services Research, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer Invest 28:46-53. 2010
    ..3% MBC), immunotherapy was associated with $285, $73, and $12 million cost increase for NHL, MCRC, and MBC, respectively. Costs for these cancers would have exceeded $1.82 billion had 50% of eligible patients received immunotherapy...
  15. ncbi Influenza vaccination among individuals with cancer and their family members
    Ya Chen Tina Shih
    Department of Biostatistics, M D Anderson Cancer Center, University of Texas, Houston, 77230 1402, USA
    Am J Prev Med 38:61-9. 2010
    ..Influenza vaccination for family members of patients with cancer lowers patients' risk of influenza and related complications...
  16. ncbi Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    J Clin Oncol 27:2007-14. 2009
    ..This study estimated the economic burden of breast cancer-related lymphedema (BCRL) among working-age women, the incidence of lymphedema, and associated risk factors...
  17. ncbi Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results
    Linda S Elting
    Health Services Research, Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Biol Blood Marrow Transplant 13:806-13. 2007
    ..In addition to its previously demonstrated clinical benefit, palifermin prophylaxis offers a favorable economic profile among patients with hematologic malignancies who receive total body irradiation and autologous stem cell support...
  18. ncbi The economic burden of supportive care of cancer patients
    Linda S Elting
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Support Care Cancer 12:219-26. 2004
    ..The goal of this study was to estimate these costs and to explore the impact of these costs on policy decisions...
  19. ncbi Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia
    Linda S Elting
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 447, Houston, TX 77030, USA
    J Clin Oncol 26:606-11. 2008
    ..We retrospectively compared the outcomes and costs of outpatient and inpatient management of low-risk outpatients who presented to an emergency department with febrile neutropenia (FN)...
  20. ncbi Labor costs associated with incontinence in long-term care facilities
    Ya-Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Urology 62:442-6. 2003
    ..52 dollars per patient per shift, UI costs an additional 13.57 dollars to treat per day, or 4957 dollars annually. Our findings can be used to capture the "averted costs" in long-term care facilities from curing UI...
  21. ncbi Factors associated with the income distribution of full-time physicians: a quantile regression approach
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas, M D Anderson Cancer Center, TX, USA
    Health Serv Res 42:1895-925. 2007
    ..We investigated factors underlying the distribution of income within the physician population...
  22. ncbi A cost-effectiveness analysis of first-line controller therapies for persistent asthma
    Ya Chen Tina Shih
    Section of Health Services Research, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Pharmacoeconomics 25:577-90. 2007
    ....
  23. ncbi Do pharmacogenomic tests provide value to policy makers?
    Ya-Chen Tina Shih
    Pharmacoeconomics 24:1173-7. 2006
  24. ncbi Factors associated with hospitalization costs for patients with community-acquired pneumonia
    Sanjay Merchant
    University of Maryland, School of Pharmacy, Baltimore, Maryland, USA
    Clin Ther 25:593-610. 2003
    ..The total cost of pneumonia, including indirect costs, was estimated to be approximately $23 billion per year in 1994...
  25. ncbi Sociological influences on antidepressant prescribing
    Betsy Sleath
    School of Pharmacy and Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Beard Hall CB 7360, Chapel Hill, NC 27599 7360, USA
    Soc Sci Med 56:1335-44. 2003
    ..Health care providers need to take the time to help patients without insurance obtain antidepressant medication if it is needed...
  26. ncbi Resource utilization associated with irritable bowel syndrome in the United States 1987-1997
    Ya-Chen Tina Shih
    MEDTAP International Inc, Bethesda, Maryland, USA
    Dig Dis Sci 47:1705-15. 2002
    ..However, a better case identification criterion is necessary to estimate the true disease burden...

Research Grants4

  1. Economic Evaluations of Emerging Genomic Tests for Early Stage Breast Cancer
    YA CHEN SHIH; Fiscal Year: 2007
    ..To estimate the budgetary impact of the emerging pharmacogenomic prognostic and/or predictive tests ..
  2. Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?
    YA CHEN SHIH; Fiscal Year: 2009
    ..This information will help project the future costs of cancer. Findings from this study will also alert policymakers to the subgroups of patients who may not benefit from innovative agents such as mAbs due to access barriers. ..
  3. Monoclonal Antibodies in Cancer Care: Is Underinsurance An Access Barrier?
    Ya Chen Tina Shih; Fiscal Year: 2010
    ..This information will help project the future costs of cancer. Findings from this study will also alert policymakers to the subgroups of patients who may not benefit from innovative agents such as mAbs due to access barriers. ..